Abstract
MP4CO, developed by Sangart Inc. (San Diego, CA), is a pegylated human hemoglobin-based carbon monoxide (CO) delivery agent and oxygen therapeutic that has shown potential to prevent and reverse red cell sickling. A double blind, comparator controlled, dose-escalation, Phase 1b study was conducted to assess the safety of MP4CO. Adult sickle cell patients with HbSS or S/β0 Thal genotype who were not experiencing a painful crisis were randomized to receive either MP4CO or normal saline (NS) in a sequential series of six escalating dose cohorts (A–F). In each cohort, three patients received MP4CO (Treatment group) and one patient received NS (Controls). Single IV doses ranged from 15 mg/kg/dose (0.35 mL/kg infusion) to 172 mg/kg/dose (4 mL/kg infusion). Two cohorts received fractionated doses of 172 or 344 mg/kg (4–8 mL/kg, given as two IV infusions, 24 h apart). Overall, 16/24 patients (66.7 %) reported mild to moderate adverse events (AEs); with 13/18 (72 %) in MP4CO group vs. 3/6 (50 %) in NS Controls. No serious adverse events (SAEs) were experienced and no deaths occurred. Most common AEs (reported by >2 patients) included headaches (mild and transient), fatigue and rash at the application site of the Holter electrodes. No treatment-emergent abnormalities in clinical lab values were noted. Vital signs, ECG readings, and pulmonary pressures remained within normal limits. The maximum increase in blood CO-Hb level was ~2 %, which returned to pre-dosing levels within 8 h after dosing. The mean increase in free plasma Hb (an index of MP4CO dose) ranged from 0.20 to 0.35 g/dL in the two highest dose cohorts, with no significant change in total whole blood hemoglobin level. There was no symptomatic or clinical evidence of renal dysfunction in either group based on serum creatinine and urinary albumin results. Two patients had elevated renal biomarkers (β2M and NAG) at Hour 72, which normalized at follow-up visits. Both patients had documented intercurrent illnesses during the study. Further testing of stored urine samples were within normal limits, which suggested the changes were reflective of a generalized inflammatory state rather than direct tubular injury.
MP4CO-SCD-105 Study Investigators: Jo Howard, MB, BChir, Guy’s and St. Thomas’ Hospital NHS Foundation Trust, London, UK; Swee Lay Thein, MBBS, DSc, King’s College Hospital NHS Foundation Trust, London, UK; Frédéric Galactéros, MD, PhD, Hôpital Henri-Mondor, Créteil, France; Adlette Inati, MD, Lebanese American University Hospital, Beirut, Lebanon; and Marvin Reid, MD, PhD, Sickle Cell Unit, University of the West Indies at Mona, Kingston, Jamaica
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ballas SK, Lusardi M (2005) Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol 79(1):17–25
Belcher JD, Young M, Chen C et al (2013) MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice. Blood 122(15):2757–2764
Belcher JD, Mahaseth H, Welch TE et al (2006) Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest 116:808–816
Winslow RM, Lohman J, Malavalli A et al (2004) Comparison of PEG-modified albumin and hemoglobin in extreme hemodilution in the rat. J Appl Physiol 97:1527–1534
Vandegriff KD, Young MA, Lohman J (2008) CO-MP4, a polyethylene glycol-conjugated haemoglobin derivative and carbon monoxide carrier that reduces myocardial infarct size in rats. Br J Pharmacol 154(8):1649–1661
Howard J, Thein SL, Keipert PE (2013) Poster presentation of MP4CO-SCD-105 study results at the American Society of Hematology (ASH) meeting. New Orleans, LA
Howard J, Thein SL, Galactéros F et al (2013) Safety and tolerability of MP4CO: a dose escalation study in stable patients with Sickle Cell disease. Blood 122(21):2205
Acknowledgments
PEK was employed by Sangart Inc. as VP, Clinical Development, during the conduct of the MP4CO-SCD-105 study.
Author information
Authors and Affiliations
Consortia
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this paper
Cite this paper
Keipert, P.E., For the MP4CO-SCD-105 Study Investigators. (2016). Clinical Evaluation of MP4CO: A Phase 1b Escalating-Dose, Safety and Tolerability Study in Stable Adult Patients with Sickle Cell Disease. In: Luo, Q., Li, L., Harrison, D., Shi, H., Bruley, D. (eds) Oxygen Transport to Tissue XXXVIII. Advances in Experimental Medicine and Biology, vol 923. Springer, Cham. https://doi.org/10.1007/978-3-319-38810-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-38810-6_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-38808-3
Online ISBN: 978-3-319-38810-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)